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Abstract
Alzheimer’s disease (AD) is the leading form of dementia worldwide. It is associated
with advanced age and involves a progressive cognitive decline. Pathologically, AD is
characterized by two defining features: neurofibrillary tangles and amyloid plaques. The
neurofibrillary tangles are composed of cleaved and hyperphosphorylated forms of the
protein tau. The amyloid plaques are aggregates of the amyloid β (Aβ) peptide. Aβ is
derived from a larger precursor protein, the amyloid precursor protein (APP), through
sequential proteolytic cleavages. APP can first be enzymatically cleaved by either α- or βsecretase. If first cleaved by α-secretase, it is cleaved within its Aβ domain; therefore, the
formation of Aβ is precluded. If first cleaved by β-secretase, subsequent cleavage by γsecretase results in the production of differentially sized Aβ peptides of 40-42 amino acids
that can accumulate to form the characteristic plaques of the disorder. Since genetic
evidence indicates that Aβ accumulation is the primary causative agent of AD, much
emphasis has been placed on elucidating factors that influence its formation. My thesis will
discuss the impact of one such influential factor: the growth-associated protein-43 (GAP-43).
I found that overexpression of GAP-43 and APP in HEK293 cells, a human embryonic
kidney cell line, results in a profound alteration of APP processing as evidenced by a
significant reduction in both α- and β-CTF fragments and that this effect is dependent on the
palmitoylation of cysteines 3 and 4 of GAP-43. To our knowledge, this paper is the first
known report to describe a functional interaction between APP and GAP-43. By shedding
light on factors that play a crucial role in determining the processing fate of APP, we gain a
better understanding of the pathology of the disease and consequently, bring ourselves closer
in the search for an effective therapy for the treatment of AD.
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Introduction
Alzheimer’s disease (AD) is the most prevalent form of dementia worldwide, afflicting
approximately 5.3 million people in the United States alone (alz.org, 2017). Due to the aging
“baby boomer” population, this number is expected to climb drastically within the next 20 years.
Currently, it is the sixth leading cause of death in the United States and is the only leading cause
that cannot be prevented, cured, or slowed (alz.org, 2017).
AD is associated with advanced age, generally manifesting in the 6th decade and beyond,
and involves a progressive cognitive decline. It is commonly divided into the early, mid, and
late stages, or alternatively, into seven clinical stages (Sheehan, 2012). In the early stages,
individuals with Alzheimer’s begin to experience memory lapses (McKhann et al., 1984). They
will occasionally misplace commonly used items and will begin to misuse words. As the disease
progresses, the symptoms become progressively more severe until the afflicted individuals can
no longer carry out necessary life functions (McKhann et al., 1984). They will no longer be able
to control their own bodily functions and will come to completely depend on others. This
downward spiral is not only devastating for the individual, but for society, as demonstrated by
the $200 billion cost associated with the care of AD patients in both the clinical and private
settings in 2014 alone (alz.org, 2014).
Although AD symptomatology has been well characterized for quite some time, it was
not until 1907 that the disease was formally characterized by Alois Alzheimer, a Bavarian
psychiatrist (Stelzmann et al., 1995). In 1907, Alois Alzheimer performed an autopsy on
Auguste Deter, a former patient of his that had experienced what today would be described as
AD-like symptoms towards the end of her life. During the autopsy, he noted two hallmark
features in her brain: extracellular plaques, which he characterized as “minute miliary foci
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caused by deposition of a particular substance in the cortex,” and intracellular neurofibrillary
tangles (Stelzmann et al., 1995). It was not until the early 1980s that Glenner and Wong
determined that the extracellular plaques were aggregates of the beta amyloid peptide (Aβ),
which has since been determined to be derived from a series of sequential proteolytic cleavages
of a larger precursor protein called the β-amyloid precursor protein (APP) (Glenner & Wong,
1984; Kang et al., 1987). It was not until the mid-1980s that Grundke-Iqbal discovered that the
intracellular neurofribrillary tangles were hyperphosphorylated and cleaved forms of the protein
tau (Grundke-Iqbal et al., 1986). These seminal findings remain the foundation upon which
investigations into the pathological underpinnings of this disease are built.
Despite the fact that AD has been symptomatically and pathologically described for over
100 years, there is still no cure nor effective treatments for this disorder. Due to its high
prevalence and destructive nature, an effective treatment option is of the utmost importance.
Because genetic evidence clearly indicates that the accumulation of Aβ is the primary
pathological manifestation in AD, most current treatment options under investigation target the
formation and/or the accumulation of Aβ. Since the formation of Aβ depends on the processing
fate of its larger precursor protein, APP, understanding factors that influence its processing
destiny is crucial. Thus, the primary goal of this study was to confirm a novel protein-protein
interaction between APP and the growth-associated protein-43 (GAP-43) as well as to
investigate any potential influence of this novel interaction on the processing fate of APP with
relevance to AD pathology and therapy.
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Literature Review
APP structure
APP belongs to a family of type I transmembrane proteins, which includes the APP like
proteins 1 and 2 (APLP1 and APLP2 respectively) (Wasco et al., 1992; Wasco et al., 1993).
Members of this family possess a long extracellular domain of approximately 600 amino acids, a
transmembrane helix, and a short intracellular domain of approximately 50 amino acids (Wasco
et al., 1992; Wasco et al., 1993). While APP shares a high degree of sequence identity with
APLP1 and APLP2 and thus, many structural similarities, only APP possesses the sequence that
encodes the Aβ domain, while APLP1 and APLP2 are divergent in this region (Wasco et al.,
1992; Wasco et al., 1993). In addition to an Aβ domain, APP also possesses several distinct
domains within its extracellular region, including: a heparin binding/growth factor like domain, a
copper binding domain, a zinc binding domain, an acidic region, and a second heparin binding
domain (Lazarov & Demars, 2012) (Figure 1). Additionally, APP possesses an intracellular tail
that contains sites for adapter protein binding as well as a YENPTY domain (Lazarov & Demars,
2012). While the extracellular domains primarily influence dimerization, stability, and
processing, the intracellular YENPTY domain is required for the proper endocytosis and
recycling of APP (Small et al., 1994; King et al., 2003; Spoerri et al., 2012; Hoefgen et al.,
2014).
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Figure 1: APP Structure

Adapted from Lazarov and Demars, 2012

Figure 1 is a schematic representation of the structure and domains of APP. APP is a type I transmembrane protein
with several extracellular and one intracellular domain. The extracellular domains include: heparin binding
domain/growth factor like domain (HBD), copper binding domain (CuBD), zinc binding domain (ZnBD), kunitztype protease inhibitor domain (KPID), a second HBD, and an Aβ domain. The intracellular domain consists of the
YENPTY domain.

It is important to note that through alternative splicing, eight APP isoforms exist;
however, only 3 are commonly expressed: APP695, APP751, and APP770, which contain 695, 751,
and 770 amino acids respectively (Kang & Müller-Hill, 1989). Although these 3 isoforms are
very similar, some differences do exist. Notably, the APP695 isoform is predominantly expressed
in neurons, while the other 2 isoforms are predominantly expressed in non-neuronal tissues
(Rohan de Silva et al., 1997). Additionally, the longer isoforms of APP, APP751 and APP770,
possess a kunitz-type protease inhibitor domain in the extracellular region, while the APP695
isoform does not (Rohan de Silva et al., 1997). Despite these differences, all APP isoforms are
modified and metabolized in a similar fashion.
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APP post-translational modifications
APP contains two potential N-linked glycosylation sites (Asn467 and Asn496) as well as a
single O-linked glycosylation site (Ser124) (McFarlane et al., 1999). The McFarlane group
demonstrated that N-linked glycosylation is required for the proper trafficking of APP to the cell
surface by treating cells stably expressing the APP695 isoform with mannosidase inhibitors
(McFarlane et al., 1999). Compared to the untreated control group, the mannosidase inhibitortreated group exhibited a higher degree of APP retention in the Golgi as indicated by enhanced
perinuclear staining of the APP protein; thus, they concluded that N-linked glycosylation is
required for the proper trafficking of APP (McFarlane et al., 1999). Another group
independently demonstrated that O-linked glycosylation serves a similar role. Using cells
overexpressing an O-linked glycosylation deficient APP mutant in which Ser124 was mutated to
Cys, Tomita et al. noted a retention of APP in the endoplasmic reticulum by confocal
microscropy as well as a decrease in overall APP processing via immunoblot analysis (Tomita et
al., 1998). Thus, they concluded that O-linked glycosylation is necessary for the targeting of
APP to the plasma membrane as well as for the processing of APP (Tomita et al., 1998).
In addition to N- and O-linked glycosylation sites, APP possesses two sulfation sites
(Tyr217 and Tyr262) and multiple phosphorylation sites (Ser198, Ser206, Ser655, and Ser675) (Walter
& Haass, 2000). Both sulfation and phosphorylation are known to impact trafficking and
protein-protein interactions; however, the precise roles of these post-translational modifications
at each of the aforementioned sites remain somewhat ambiguous. Nevertheless, it is well
established that these critical post-translational modifications influence the processing fate of
APP (Tomita et al., 1998; Walter & Haass, 2000; Tamayev et al., 2009).
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APP processing and its metabolites
APP695 can be processed through one of two mutually exclusive pathways: nonamyloidogenic or amyloidogenic (Figure 2), so named because the latter pathway leads to the
formation of extracellular amyloid deposits composed of the A peptide, while the former
pathway generates different metabolites that do not have the propensity to aggregate (Selkoe,
2011). Thus, since the amyloidogenic pathway is associated with amyloid accumulation, it is
also associated with disease onset, while the non-amyloidogenic pathway, which is not
associated with amyloid accumulation, is not (Selkoe, 2011). It is important to note that both
pathways occur in all tissues that express APP.
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Figure 2: APP Processing
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Figure 2 is a schematic representation of the processing of APP. APP can be processed through one of two
mutually exclusive pathways: non-amyloidogenic or amyloidogenic. In the non-amyloidogenic pathway, APP is
first cleaved by α-secretase (2a) within its Aβ domain. This results in the release of a soluble fragment, sAPPα (2b),
that is released extracellularly and a carboxyl-terminal fragment, α-CTF (2c), that remains in the membrane. α-CTF
is subsequently cleaved by γ-secretase to produce a soluble p3 fragment (2d) which is released into the extracellular
medium and an AICD fragment (2e) that is released into the cytosol. In the amyloidogenic pathway, APP is cleaved
first by β-secretase (2f) which results in the production of sAPPβ (2g) that is released into the extracellular medium
and a carboxyl-terminal fragment, β-CTF (2h), that remains in the membrane. β-CTF is subsequently cleaved by γsecretase to produce the neurotoxic Aβ peptide (2i) that is released extracellularly and the AICD fragment (2j) that
is released into the cytosol.

In the non-amyloidogenic pathway, APP is first cleaved by α-secretase, a zinc
metalloproteinase activity that is mediated by members of the ADAM (A Disintegrin and
Metalloprotease) family of proteins (a family of type I transmembrane enzymes), at residue 612
(APP695 numbering will be used throughout this document) (Roberts et al., 1994) (Figure 2a).
Of the ADAM family of proteins, ADAM10 appears to be the primary effector of α-secretase
activity (Lammich et al., 1999). Cleavage of APP by α-secretase precludes the formation of Aβ,
since α-secretase cleaves APP within the Aβ domain (Esch et al., 1990). Cleavage of APP by αsecretase results in the formation of a soluble APP fragment, sAPPα, that is released into the
extracellular medium (Figure 2b) and a carboxyl-terminal fragment, α-CTF, that remains in the
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membrane (Esch et al., 1990; Roberts et al., 1994; Lammich et al., 1999) (Figure 2c). The αCTF fragment is subsequently cleaved within its transmembrane domain by γ-secretase, a
complex consisting of four components: presenilin (PS, PS1, or PS2), nicastrin (NCT), anterior
pharynx-defective-1 (APH-1), and presenilin enhancer 2 (PEN-2) (Kimberly et al., 2003).
Presenilin is the catalytic component of the complex, while the other proteins serve to activate
the pro-enzyme and regulate activity (Wolfe et al., 1999). Cleavage of α-CTF at residues 636638 by γ-secretase results in the formation of two products: an extracellular fragment called p3
(Figure 2d) and an intracellular fragment called the APP intracellular domain (AICD) (Figure
2e).
The products of the non-amyloidogenic pathway are soluble and nontoxic. Although still
under debate, some studies have found evidence that the products of the non-amyloidogenic
pathway provide neurotrophic benefits. For instance, sAPPα has been implicated in CNS
development, neuronal plasticity, and survival (Zhang et al., 2011). In support of its role in
neuronal plasticity and survival, Thornton et al. found that intracerebroventricular administration
of sAPPα shortly after traumatic brain injury in rats results in improved motor outcome as well
as in a reduction in the number of apoptotic axons as compared to the vehicle-treated controls as
determined using the rotarod test and immunohistochemical analysis using an antibody against
caspase 3 (a marker of apoptosis) respectively (Thornton et al., 2006). Additionally, AICD, a
fragment that results from both non-amyloidogenic and amyloidogenic processing, has been
implicated in regulating the transcription of several genes (Kinoshita et al., 2002; von Rotz et al.,
2004). In support of this function, Zhou et al. found that AICD indirectly regulates gene
transcription by inhibiting Wnt signaling, a pathway that is involved in cellular proliferation, cell
polarity, and cell fate determinations (Zhou et al., 2012). They found that AICD interacts with
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glycogen synthase kinase-3 β (GSK3β) and that this interaction facilitates the formation of the
Axin-GSK3β complex and consequently, the phosphorylation and degradation of β-catenin
(Zhou et al., 2012). This in turn decreases the transcription of several genes including c-Myc,
with the end result being reduced proliferation and enhanced differentiation (Zhou et al., 2012).
Additionally, another group found that AICD effectively regulates its own production as the APP
gene was identified as one of the transcriptional targets of AICD (von Rotz et al., 2004).
Although both sAPPα and AICD are believed to possess neurotrophic properties, the fragment
p3 has not been associated with any physiological role as it is rapidly degraded (Zhang et al.,
2011). Thus, although the precise roles for these metabolites are still somewhat ambiguous, it is
clear that the manner in which APP is metabolized in the non-amyloidogenic pathway results in
products that are not associated with the disease state.
In the alternative pathway, APP is first cleaved by β-secretase, a membrane-bound
aspartyl protease identified to be BACE1 (β-site APP Cleaving Enzyme 1) (Figure 2f) (Vassar,
1999). Cleavage of APP at residue 596 by β-secretase results in the release of a truncated,
soluble APP fragment, sAPPβ, that is released extracellularly (Figure 2g) and a carboxylterminal fragment, β-CTF, that remains in the membrane (Figure 2h) (Seubert et al., 1993; Sinha
& Lieberburg, 1999). β-CTF is subsequently cleaved by γ-secretase at residues 636-638, which
releases an extracellular fragment, Aβ (Figure 2i), and an intracellular fragment, AICD (Figure
2j) (Seubert et al., 1993; Sinha & Lieberburg, 1999). Since cleavage of β-CTF by γ-secretase
can occur at a variety of sites, a spectrum of differentially sized Aβ fragments of approximately 4
kilodaltons (kDa) results, the majority species being Aβ40 and the more amyloidogenic being
Aβ42 (Zhang et al., 2011).
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The products of the amyloidogenic pathway are not all soluble and some are even toxic.
Evidence supports sAPPβ as a ligand for death receptor 6 and as a regulator of neuronal cell
death (Zhang et al., 2011). In support of this, Nikolaev et al. discovered that trophic factor
deprivation results in the release of sAPPβ and its binding to death receptor 6 on neuronal cells,
which in turn activates caspase 6-dependent apoptosis (Nikolaev et al., 2009). In addition to
sAPPβ, the amyloidogenic pathway also produces the neurotoxic Aβ peptide. The toxicity of the
Aβ peptide is well established and is discussed in more detail in the following section.

The role of β-amyloid in Alzheimer’s pathology
As briefly mentioned above, the neurotoxic properties of Aβ are well established. These
toxic properties are dependent upon the oligomerization and accumulation of the peptide into
plaques. It is important to note that the Aβ peptide can, once metabolically released from APP,
be cleared through physiological clearance mechanisms such as breakdown by insulin degrading
enzyme and removal by carrier proteins like transthyretin and apolipoprotein E (Blancas-Mejía
& Ramirez-Alvarado, 2013; Baranello et al., 2015). However, if not cleared by one of these
mechanisms, Aβ accumulates and forms plaques. Aβ plaque formation in the brain is an
obligatory pathological feature of AD. Three primary lines of evidence support this: 1) In
familial AD, the gene encoding tau has not been shown to be mutated; rather, tau mutations
result in a distinct form of dementia known as frontotemporal dementia that is separate from AD
(Selkoe, 2011; Mackenzie & Neumann, 2016). 2) Numerous incidents have been reported in
which individuals with late onset AD present with few neurofibrillary tangles (Selkoe, 2011). 3)
All familial forms of AD have been shown to stem from mutations in genes that result in the
increased production and/or accumulation of Aβ (Selkoe, 2011). This includes APP gene
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duplication events and mutations in the APP gene in regions encoding the Aβ peptide as well as
in the enzymes responsible for generating Aβ. In addition to these three lines of evidence, a
protective mutation has recently been identified in the gene encoding APP near the N-terminal
portion of the Aβ region (Jonsson et al., 2012). This mutation has been found to reduce the
amount of Aβ formed and is found at a much higher prevalence in the elderly without AD; thus,
further supporting the causative role of Aβ in AD pathology (Jonsson et al., 2012; Maloney et
al., 2014).
Once formed, the aggregation of Aβ is a crucial event in the toxic gain-of-function
change that occurs in the disease state (Lorenzo & Yankner, 1994; Larson & Lesné, 2012). In
the aggregated state, Aβ changes from a soluble conformation to an amyloid conformation
(Lorenzo & Yankner, 1994). Although the focus of this study is on the production of Aβ from
the APP protein, it is important to note that amyloid proteins, defined as having a high beta-sheet
content and red-green birefringence when stained with the histological dye Congo-red, can be
produced by several different proteins, such as transthyretin, often as a consequence of a
misfolding event (Lorenzo & Yankner, 1994). Since amyloid proteins are insoluble in nature
and highly resistant to proteolytic clearance, they are known to aggregate and are associated with
toxicity in several disease states collectively known as the amyloidoses (Blancas-Mejía &
Ramirez-Alvarado, 2013). Furthermore, these diseases are not restricted to the brain; rather, they
can impact several tissues such as the heart, the liver, and muscles (Blancas-Mejía & RamirezAlvarado, 2013). Within the brain, amyloid is thought to disrupt neuronal function by toxic
effects at the synapse that cause synaptic loss and neuronal cell death (Selkoe, 2011). The toxic
nature of amyloid proteins further supports the causative role of Aβ in Alzheimer’s disease as
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does the fact that all genetic links to AD result in the increased production and/or accumulation
of the Aβ peptide.

Genetic links to AD
As briefly mentioned, several different mutations have been identified in APP, as well as
in proteins that regulate the processing of APP, that result in increased Aβ production and/or
accumulation (Selkoe, 2011; Lanoiselée et al., 2017). As of this writing, 52 APP, 238 PSEN1,
and 45 PSEN2 mutations have been linked to autosomal dominant forms of AD, while carriers of
the Apolipoprotein E (APOE) ε4 allele are associated with sporadic forms of AD (Campion et
al., 1999; Liu et al., 2013; Lanoiselée et al., 2017).
Mutations in the APP protein have been identified around the β- and γ-secretase cleavage
sites as well as within the Aβ domain. More specifically, two mutations have been identified
around the β-secretase cleavage site (Mullan et al., 1992). Located at positions 670 and 671,
these two mutations occur simultaneously in what is referred to as the Swedish mutant of APP
(APPSWE) and result in an increase in the overall production of all Aβ species (Mullan et al.,
1992). While mutations that cluster around the β-secretase cleavage site result in enhanced Aβ
production, those that cluster around the γ-secretase cleavage site and those within the Aβ
domain itself increase the production of Aβ42, the more amyloidogenic species, and
consequently, enhance Aβ aggregation (De Jonghe, 2001; Selkoe, 2011). Additionally,
overexpression of wild type APP as the result of gene duplication, such as with trisomy 21,
results in the increased production of all Aβ species, similar to the impact β-secretase cleavage
site mutations have on Aβ production (Masters et al., 1985; Citron et al., 1992; Mullan et al.,
1992; Selkoe, 2011; Potter et al., 2016). Thus, autosomal dominant APP mutations result in the
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enhanced formation and accumulation of Aβ plaques, earlier disease onset, and a more rapid
progression of the disease.
Mutations in PSEN1 and PSEN2 are also implicated in autosomal dominant forms of AD
(Levy-Lahad et al., 1995; Campion et al., 1999; Tanzi & Bertram, 2005b; Lanoiselée et al.,
2017). All the identified mutations in PSEN1 and PSEN2 have been found to increase the
production of Aβ42, which ultimately increases the production and accumulation of Aβ plaques
(Levy-Lahad et al., 1995; Rogaeva E, 2001; Tanzi & Bertram, 2005a). As with the APP
mutations, these autosomal dominant mutations result in earlier disease onset and a more rapid
progression of the disease.
Although not causative of familial AD, individuals carrying the APOE ε4 allele are at a
much higher risk (up to 5 times greater) for developing AD as compared to those carrying other
APOE variants such as APOE ε2 (Michaelson, 2014). It is well established that APOE ε4
carriers are not able to clear Aβ as efficiently as non-carriers (Schmechel et al., 1993;
Michaelson, 2014). It is hypothesized that the ε4 variant, which normally functions to clear
cholesterol from the body, is not as effective at clearing lipids, which promotes the aggregation
of Aβ oligomers and hence, plaque formation (Schmechel et al., 1993; Selkoe, 2011; Liu et al.,
2013; Michaelson, 2014).
It is important to note that all of the aforementioned mutations result in the enhanced
production and/or accumulation of Aβ. Since the generation of Aβ is the primary causative
agent of AD, and since the formation of Aβ depends upon the processing fate of APP, identifying
the subcellular locations in which APP undergoes amyloidogenic versus non-amyloidogenic
processing is critical.
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APP subcellular localization and trafficking
The processing fate of APP is determined to a large extent by its subcellular location,
which in turn is dependent upon its synthesis and trafficking. After synthesis in the rough
endoplasmic reticulum, APP is modified in the Golgi complex and then transported down the
axon via fast anterograde transport to the cell membrane (Figure 3). At the plasma membrane,
α-secretase is primarily responsible for the cleavage of APP (Lammich et al., 1999). However,
APP can be reinternalized into the endo-lysosomal pathway before cleavage by α-secretase (Koo
& Squazzo, 1994). In endosomes and lysosomes, APP is primarily cleaved by β-secretase (Koo
& Squazzo, 1994). Alternatively, once internalized from the plasma membrane, APP can be
returned to the trans-Golgi network (TGN) via retrograde transport where α- and β-secretase
compete for the cleavage of APP and where the majority of APP has been found to reside (Choy
et al., 2012). While it is now clear that the processing fate of APP is largely dependent upon its
subcellular location and consequently its trafficking pattern, the factors that influence the
trafficking patterns and subcellular distribution of APP still remain a mystery. One possible
factor that may potentially influence the internal trafficking of APP and consequently its
processing fate is the focus of this study: growth-associated protein-43 (GAP-43).
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Figure 3: APP Trafficking
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Figure 3 depicts the subcellular trafficking of APP. APP is synthesized in the rough endoplasmic reticulum (3a)
and then transported down the axon via fast anterograde transport to the Golgi complex (3b) for processing before
being inserted in the plasma membrane. If not processed by α-secretase at the plasma membrane, APP can be
reinternalized into endosomes (3c) or degraded by lysosomes (3d). In endosomes, if not processed by β-secretase, it
can be trafficked to the Golgi complex (3e) or shuttled to the rough endoplasmic reticulum (3f) via retrograde
transport.

GAP-43 structure
GAP-43, which is also known as neuromodulin, B-50, P-57, F1, and pp46, is encoded by
three exons located on human chromosome 3 (Grabczyk et al., 1990; Holahan, 2017). The first
exon codes for the 5’ untranslated region (UTR) and the N-terminal 10 amino acids (Grabczyk et
al., 1990). The second exon codes for the majority of the coding region and the third codes for
the remainder of the coding region and the 3’ UTR (Grabczyk et al., 1990). The end result is a
23.6 kDa, 226 amino acid protein (Rosenthal et al., 1987). Although the calculated molecular
mass of GAP-43 is 23.6 kDa, it typically migrates at 40-60 kDa when assayed by protein
electrophoresis due to its highly hydrophilic nature (Rosenthal et al., 1987). The high prevalence
of charged amino acids also accounts for its primarily linear tertiary structure (Figure 4);
however, a complete crystal structure has not yet been achieved (Hayashi et al., 1997). Although
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GAP-43 is a highly hydrophilic protein, it does contain a small hydrophobic region in its Nterminal domain, which plays an integral role in membrane attachment (Skene JH, 1989). In
addition to a membrane binding domain, GAP-43 also possesses an effector or IQ domain that
extends from amino acids 38-56 and which contains the protein kinase C phosphorylation site at
amino acid 41 (Akers & Routtenberg, 1985; Alexander et al., 1988). Phosphorylation at this site
is implicated in actin polymerization, long-term potentiation, and neurotransmitter release
(Heemskerk et al., 1990; Benowitz & Routtenberg, 1997; He et al., 1997). Additionally, GAP43 contains a calmodulin (CaM) binding domain, which plays a role in neurotransmitter release
as well as several phosphorylation sites, which play a role in synaptic plasticity and cellular
morphology (Biewenga, 1996; Gamby et al., 1996; Holahan, 2017). The various domains of
GAP-43 allow for a variety of complex post-translational modifications to occur such as
phosphorylation, CaM binding, and palmitoylation.
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Figure 4: GAP-43 Structure
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Figure 4 is a schematic representation of the primarily linear structure of GAP-43. GAP-43 contains a small basic
region near its N-terminus as well as an IQ/calmodulin (CaM) binding domain. The IQ/CaM binding domain also
possesses a protein kinase C phosphorylation site at amino acid 41.

GAP-43 palmitoylation
GAP-43 can be dually acylated by palmitate and/or sterate causing association with the
ER-Golgi intermediate compartment, Golgi apparatus, and the plasma membrane (Skene JH,
1989). Although palmitoylation/acylation is required for the initial targeting of GAP-43 to the
plasma membrane, Liang et al. observed that only 35% of GAP-43 at steady state is fatty
acylated, while nearly 100% is membrane-bound (Liang et al., 2002). Therefore, they concluded
that palmitoylation is not necessary for GAP-43 to maintain attachment to the plasma membrane
(Liang et al., 2002). Using mass spectrometric methods, Liang and colleagues showed that once
associated with the plasma membrane, the basic residues at the N-terminus of GAP-43 are
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critical for maintenance of membrane association (Liang et al., 2002). Although not required for
maintaining GAP-43 at the plasma membrane, palmitoylation is required for the initial targeting
of GAP-43 to the membrane and transcytosis to the axon (El-Husseini et al., 2001; Liang et al.,
2002). Liu, Fisher, and Storm confirmed this finding as they demonstrated that GAP-43
palmitoylation-deficient mutants are primarily localized in the cytosol, while their palmitoylated
counterparts are membrane-bound (Liu et al., 1994). The capacity of GAP-43 to undergo
palmitoylation as well as its other aforementioned post-translational modifications allow it to
perform a myriad of physiological roles.

Physiological roles of GAP-43
Several studies have verified the role of GAP-43 during neural development and
regeneration, including those conducted by Maier et al. In 1999, Maier and colleagues noted that
GAP-43 double knock out mice demonstrated abnormal neural development and lethality shortly
after birth; thus, they concluded that GAP-43 is required for neural development (Maier et al.,
1999). Due to the pivotal role of GAP-43 during neural development, it is not surprising that
GAP-43 expression levels peak during development and decline drastically after birth except in
associative areas of the brain and the hippocampus where GAP-43 levels remain relatively high
(Benowitz & Routtenberg, 1997). Due to this expression pattern, GAP-43 has also been
implicated in learning processes (Benowitz & Routtenberg, 1997). By using a transgenic mouse
line overexpressing either wild type GAP-43, a non-phosphorylatable form of GAP-43, or a
constitutively phosphorylated form, Routtenburg and others found that overexpression of the
constitutively phosphorylatable form results in enhanced long-term potentiation and significantly
fewer errors in a Win-Shift delay behavioral assay, thus indicating that phosphorylation of GAP-
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43 is required for learning (Routtenberg et al., 2000). In addition to playing a vital role in neural
development and learning, GAP-43, by mediating actin dynamics, is also responsible for growth
cone formation, filopodia formation, neurite outgrowth, and cell shape (Aigner & Caroni, 1993;
Nguyen et al., 2009; Grasselli et al., 2011). Using cultured dorsal root ganglia neurons depleted
of GAP-43, Aigner and Caroni demonstrated the necessity of this protein in growth cone
formation as well as axon guidance in response to external growth cues (Aigner & Caroni, 1993).
Additionally, Nguyen, He, and Meiri found that overexpression of a constitutively
phosphorylated form of GAP-43 results in F-actin polymerization and growth cone formation,
whereas overexpression of an unphosphorylatable form of GAP-43 in the same cell line induces
neurotubulin assembly and neurite outgrowth (Nguyen et al., 2009). In further support of this,
Grasselli and others determined that GAP-43 maintains climbing fibre structure; is necessary for
axonal sprouting and regenerative potential; and mediates axon length, the number of branching
fibres, and the number and density of varicosities (Grasselli et al., 2011). GAP-43 has also been
implicated in signal transduction systems. Caprini and colleagues demonstrated that GAP-43
stimulates the release of Ca+2 from the endoplasmic reticulum in response to hypotonicity and
thus, plays an important role in signal transduction as well as in neurotransmitter release (Caprini
et al., 2003). GAP-43 has also been implicated in endocytosis as it has been shown to interact
with Rab5 to mediate endocytosis and vesicle recycling (Neve et al., 1998). Although it is clear
that GAP-43 is capable of performing a multitude of physiological roles, the expression profile
of GAP-43 restricts its functions in both a time- and space-dependent manner.
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Expression of GAP-43
As previously mentioned, GAP-43 is ubiquitously expressed throughout the brain during
development, but is restricted to certain areas of the adult brain (Benowitz & Routtenberg, 1997).
In the adult brain, GAP-43 is predominantly expressed in neurons of the hippocampus,
amygdala, cortex, and midbrain, all of which are impacted in AD (Rosenthal et al., 1987). This
expression profile is controlled by a variety of extracellular and intracellular factors (Biewenga,
1996).
The extracellular factors that control the expression pattern of GAP-43 include sex
hormones and brain injury/trauma (Biewenga, 1996). The expression profile of GAP-43 is
differentially regulated by sex hormones in the developing brain, certain areas being stimulated
by androgen (bed nuclei of the stria terminalis and the medial preoptic nuclei) and others by
estrogen (cortex and ventromedial hypothalamus) (Shughrue & Dorsa, 1994). On the other hand,
brain injury/trauma consistently results in the up-regulation of GAP-43 mRNA (Doster et al.,
1991; Chong et al., 1992). The intracellular factors that regulate its expression include protein
kinase C (PKC) and cyclic AMP (cAMP), both of which enhance GAP-43 mRNA expression
(Biewenga, 1996).
It is evident that GAP-43 expression is tightly regulated by a variety of factors.
However, this expression pattern is altered in the brains of individuals with AD. Of note, de la
Monte, Ng, and Hsu noted that postmortem individuals with AD exhibited a decrease in
expression of GAP-43 in neurons and an increase in expression of GAP-43 in white matter in the
cerebral cortex as compared to aged controls (de la Monte et al., 1995). What causes this change
in expression and its physiological relevance is still unclear. Despite this uncertainty, it is known
that once GAP-43 is expressed, it undergoes a variety of post-translational modifications,
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including palmitoylation by palmitate and/or sterate at Cys3 and Cys4, which plays an essential
role in the trafficking of GAP-43 (Skene JH, 1989; Biewenga, 1996).

GAP-43 transport
Although most membrane-bound proteins are translated in the rough ER, GAP-43 mRNA
is translated by free ribosomes in the cytosol (Denny, 2006). Shortly after translation, it
associates with membranes of the early secretory pathway as the result of palmitoylation (Skene
JH, 1989). As GAP-43 traverses this membranous network, it undergoes post-translational
modifications (Biewenga, 1996). Once fully mature, GAP-43 is targeted to the growth cones of
neuronal cells in vesicles via fast, anterograde transport (Skene & Willard, 1981b; a; Skene &
Willard, 1981c). Alternately, GAP-43 mRNA can be transported directly to the growth cones of
neurons via unknown means (Smith et al., 2004). Once at the growth cone, GAP-43 mRNA is
stabilized by the protein HuD, an RNA-binding protein, and translated by free-floating
ribosomes (Smith et al., 2004). The significance of this form of translation is unclear, but it is
reasonable to hypothesize that it may play a role in rapid changes in growth cone formation,
filopodial formation, and the modulation of actin dynamics (Smith et al., 2004).
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Statement of Proposed Research
Since the initial discovery of the pathological hallmarks of the disease by Alois Azheimer
nearly 110 years ago, the mechanism of disease onset and progression has become clearer
(Stelzmann et al., 1995; Sanabria-Castro et al., 2017; Wang et al., 2017). Evidence strongly
implicates Aβ as the primary causative agent (Selkoe, 2011; Jonsson et al., 2012; Maloney et al.,
2014; Mackenzie & Neumann, 2016). Additionally, it is well established that Aβ is derived from
the amyloidogenic processing of a larger precursor protein called APP (Figure 2). However, it
is also known that there is an alternative pathway by which APP can be processed, the nonamyloidogenic pathway (Figure 2). What we don’t know, and what is crucial to determine, are
the factors that influence the processing destiny of APP. Several labs have shown that the
processing fate of APP is influenced by its interacting partners (Russo et al., 2005; Norstrom et
al., 2010; Hao et al., 2011). Therefore, a great need exists to determine the in vivo interactome
of APP. If we can determine all the players in AD and their individual roles, we can gain a better
understanding of the pathology of the disease which is essential for the design of an effective
treatment option.
In order to address this pertinent question, Norstrom and colleagues assessed the native
APP interactome in brain using mice generated to express human APP695 fused to a C-terminal
affinity tag (Norstrom et al., 2010). The use of a C-terminal affinity tag circumvented the need
for antibodies targeted toward the C-terminus of APP. This is significant as it allowed for the
identification of overexpressed APP without interfering with the binding sites of potential APPinteracting proteins. Norstrom and colleagues purified the complexes using rabbit IgG coated
magnetic beads and subsequently performed mass spectrometry on the eluates in order to
identify novel interacting partners (Norstrom et al., 2010). The validity of their experimental
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approach was confirmed by the presence of several well-known APP-interacting proteins in the
purified complexes, including Fe65 and APLP1 and 2 (Norstrom et al., 2010). Additionally,
several novel proteins were identified as potential APP-interacting proteins (Norstrom et al.,
2010).
Norstrom et al. went on to confirm and characterize a novel APP-NEEP21 interaction
(Norstrom et al., 2010). However, the validity of the other potential APP-interacting proteins
remained to be determined. Of note, GAP-43 stood out as another prime, investigative target.
Although GAP-43 could have co-purified with affinity tagged APP695 as the result of a nonspecific interaction, several other lines of evidence support the idea of a potential APP-GAP-43
interaction.
Further supporting the hypothesis of an APP-GAP-43 interaction, is the fact that GAP-43
possesses several of the same physiological roles as APP (Table 1). Proteins possessing similar
functions often overlap spatially as well, thus, increasing the likelihood of an in vivo interaction.
This is indeed the case for APP and GAP-43 as both proteins are known to localize to several of
the same subcellular locations (Figure 5). More backing for this rationale comes from the
collective findings of several independent laboratories that implicate a potential role of GAP-43
in AD pathogenesis. For instance, Masliah and colleagues observed that APP is colocalized with
GAP-43 in 57.5 +/- 11% of the aberrant sprouting neurites associated with AD pathology and 3.3
+/- 0.4% of presynaptic terminals (Masliah et al., 1992). Additionally, in a separate study
conducted by the same laboratory, they found that in AD brains, GAP-43 protein expression is
significantly reduced in the frontal cortex and the hippocampus, areas of the brain profoundly
impacted in AD, as compared to non-demented, aged controls (Masliah et al., 2001). Other
groups found similar results in which a reduction in GAP-43 protein and/or mRNA levels were
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observed in AD brains relative to non-demented, aged controls (Coleman et al., 1992; Masliah et
al., 1992; de la Monte et al., 1995; Cheetham et al., 1996; Masliah et al., 2001). Several
laboratories have also noted a change in the distribution of GAP-43 protein expression between
AD and age-matched control brains. For instance, de la Monte, Ng, and Hsu noted that
postmortem individuals with AD exhibited a decrease in expression of GAP-43 in neurons and
an increase in expression of GAP-43 in white matter as compared to aged controls (de la Monte
et al., 1995). Although this data is correlative in nature, it indicates that GAP-43 may play a
pathophysiological role in AD; and importantly, the sum total of these findings strongly indicate
that APP and GAP-43 may interact in a bona fide protein complex with functional consequences
relevant to AD pathogenesis. Thus, we chose to investigate and characterize a possible APPGAP-43 neuronal protein interaction.

Table 1: Physiological Roles of APP and GAP-43

Table 1 depicts a comparison of the physiological roles of APP to GAP-43 as well as the sources from which the
information was derived. A (+) indicates the protein has been implicated in the physiological function and a (–)
indicates it has not.
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Figure 5: APP and GAP-43 Subcellular Localization
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Figure 5 depicts the subcellular locations at which APP and GAP-43 are known to localize.

Hypothesis
I hypothesize that GAP-43 interacts with and influences the processing of APP and may
consequently play an important physiological role in modulating the levels of Aβ produced
during APP processing.

Aims
1. Determine the effect of GAP-43 expression on the formation of APP metabolites in a relevant
cell line.
2. Confirm a potential novel APP-GAP-43 interaction.
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Methods
In order to test my hypothesis and aims, four different experimental designs were
employed, all of which followed a similar sequence of events. Briefly, cells were transfected to
over- or underexpress proteins of interest, expression/silencing was allowed for 40 to 48 hours,
cells were lysed, and lysates analyzed via Western blot analysis. A more detailed explanation of
the methods employed for these studies is provided below. Where variations on these protocols
were used, they will be noted in the text.

Transformation and plasmid purification
To generate plasmid cDNA for transfection, 100ng of plasmid vector containing the
cDNA representing the open reading frames of the proteins of interest were combined with
DH5α cells in microcentrifuge tubes. The mixture was incubated on ice for 5 minutes and then
transferred to a 42°C water bath for 30 seconds after which they were placed back on ice for 2
minutes. Luria Broth (LB) liquid growth medium (1% w/v Peptone, 0.5% w/v yeast extract,
0.5% sodium chloride) was then added and the mixtures were incubated at 37oC with shaking for
one hour. The transformed cells were plated on LB/agar plates supplemented with 50μg/mL
ampicillin and then incubated overnight at 37°C. Isolated colonies were selected and each
individual colony was incubated in 3mL LB supplemented with 50μg/mL ampicillin at 37°C
overnight on a shaker at 250rpm. Cultures were pelleted by centrifugation at 8,000rpm for 2
minutes at room temperature and the pellets purified by alkali lysis combined with pH-based
matrix using the GeneJET Plasmid Miniprep Kit (Fermentas) according to the manufacturer’s
protocol. DNA quantity and purity were analyzed using spectrophotometric analysis at 260 and
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280 nanometers absorbance. Plasmid purity was assessed by the ratio of 260:280 and needed to
be in the range of 1.8+/- 0.1.

Cell culture
N2a mouse neuroblastoma cells and human embryonic kidney 293 (HEK293) cells were
acquired from the American Type Culture Collection (ATCC – Manassas, VA) and were grown
in Delbeco’s Modified Eagle’s Medium (DMEM – Life Technologies) supplemented with 10%
fetal bovine serum and 1% penicilin/streptomycin. The cells were incubated at 37°C under 5%
CO2 and passaged 1:10 every 3-4 days.

Transfection
The day before transfection, HEK293 cells were plated at a density of 600,000 cells per
30mm cell culture dish. The following day, the cells were visually inspected to confirm that cell
confluency was between 70-90%, and if so, the cells were transiently co-transfected with 1μg of
purified plasmid cDNA using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
protocol. Expression was allowed for 40-48 hours at 37°C under 5% CO2. Table 2 lists the
plasmid cDNA constructs used for transfection. The specific constructs utilized in each
experiment are noted in the text.
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Table 2: Plasmid cDNA and Expression Vectors

Plasmid cDNA
Constructs

Expression Vector

pEYFP

pAG3

GAP-43

pAG3

GAP-43 CCAA

pAG3

APPSWE

pCMV

APP695-MYC

pCB6

Table 2 depicts the plasmid cDNA constructs and expression vectors utilized in the transfection experiments.

Generation of stable cell lines
HEK293 cells were transfected as outlined above with 1μg of pAG3 plasmid containing
FLAG-tagged versions of either GFP, GAP-43, or GAP-43 CCAA using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s protocol. Expression was allowed for 40-48 hours
at 37°C under 5% CO2 after which selection of stably expressing cells was performed using
Geneticin (Invitrogen) at 400µg/mL. Medium was changed every two days until stably
expressing cells were selected. Cells were split into fresh plates and selective pressure was
maintained at 80µg/mL Geneticin.

siRNA
Four different siRNA constructs (siRNA1-4) and a control were purchased from
QIAGEN. Each construct targeted a different sequence present on Gap-43 mRNA (Table 3). 40
picomoles of each siRNA construct was transiently transfected into N2a cells, either alone or in
combination, using the transfection protocol previously described.
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Table 3: siRNA Constructs and Target Sequences

Table 3 depicts the target sequences that correspond to each of the four siRNA constructs and the control.

Cell lysis
After 40-48 hours of expression, cells were lysed on ice according to the following
protocol. 200μL of medium were removed from each plate and transferred to microcentrifuge
tubes to which the protease inhibitor phenylmethylsulfonyl fluoride (PMSF) was added to a final
concentration of 2μM. The remaining medium was discarded and the monolayers of cells were
washed twice with 1mL of ice-cold phosphate buffered saline (PBS) at 1x without calcium or
magnesium. The 1x PBS was removed by vacuum and the cells were then incubated in 200µL
of lysis buffer (50mM Tris pH 7.4, 150mM NaCl, 1mM EDTA, 0.5% IGEPAL, 0.5%
Na:deoxycholate and a protease inhibitor cocktail (Sigma-Aldrich)) for 5 minutes on ice during
which time the microcentrifuge tubes containing the medium were centrifuged for 2 minutes at
16,000 x g and the resultant supernatants transferred into new microcentrifuge tubes and the
pellets discarded. The cells in the lysis buffer were then transferred to fresh microcentrifuge
tubes, vortexed briefly (1-2 seconds), and centrifuged for 1 minute at 16,000 x g to remove
nuclei and insoluble cell debris. The resultant supernatants were transferred to new
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microcentrifuge tubes and the pellets discarded. The lysis contents were analyzed for protein
concentration using the BCA method (Pierce).

Western blot
For analysis of the lysates by Western blot, equal protein concentrations, 20μg, were
separated on Tris/glycine/SDS polyacrylamide gels (Bio-Rad) or hand-poured Tris/tricine/SDS
gels (Miller et al., 2016). The acrylamide concentration of each gel was determined by the
relative sizes of the proteins to be detected and is noted where appropriate. After electrophoretic
separation, proteins were transferred onto polyvinylide fluoride membranes (Bio-Rad) in a
tris/glycine buffer for 1 hour 15 minutes at 350mA or overnight at 90mA. Upon completion of
the transfer, the membranes were washed 3 times with 1x PBST (phosphate buffered saline and
0.1% Tween® 20) for 5 minutes each with rocking at room temperature and then blocked with
5% milk in 1x PBST for 45 minutes at room temperature with rocking. The membranes were
then transferred to containers containing the appropriate primary antibody diluted in 1x PBST
with 1% milk and then incubated on a rocker at room temperature for 3 hours or at 4°C
overnight. After incubation, the membranes were washed 3 times for 5 minutes each with 1x
PBST at room temperature with rocking and then incubated with the appropriate secondary
antibody in 1x PBST with 1% milk with rocking for 1 hour at room temperature. The
membranes were then washed 4 times for 5 minutes each with 1x PBST at room temperature
with rocking and briefly rinsed with distilled water before antibody detection by
chemiluminesence. Immunoreactivity was visualized using SuperSignal West Pico
Chemiluminescent Substrate (Thermo Scientific) and visualized using FluorChem HD2 imager
or Aplegen OmegaLum G imager.
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Antibodies
APP polyclonal antibody CTM1, a kind gift from Dr. Gopal Thinakaran, was raised
against the C-terminus of APP with a C-myc epitope tag and provided as serum (Thinakaran et
al., 1998). Monoclonal antibody 26D6, also graciously provided by Dr. Gopal Thinakaran, was
raised against the N-terminal region of the Aβ peptide; of note, it also detects sAPPα since it
contains the same sequence (Thinakaran et al., 1998). Polyclonal antibody raised against
recombinant GAP-43 was purchased from EMD Millipore (AB5220). Affinity purified rabbit
anti-FLAG antibody detecting the FLAG epitope, DYDDDDK, was purchased from Sigma
Aldrich. Mouse anti-actin antibody was purchased from Santa Cruz Biotechnology. All
secondary antibodies, goat anti-rabbit HRP and rabbit anti-mouse HRP, were acquired from
Pierce-Thermo Scientific. See Table 4 for antibodies and dilutions.

Table 4: Antibodies and Dilutions
Antibody

Dilution

Secondary Antibody

Dilution

CTM1

1:2,000

anti-rabbit

1:40,000

26D6

1:1,000

anti-mouse

1:10,000

anti-GAP-43

1:1,000

anti-mouse

1:10,000

anti-FLAG

1:10,000

anti-rabbit

1:40,000

anti-Actin

1:10,000

anti-mouse

1:10,000

Table 4 lists the primary antibodies, the corresponding secondary antibodies, and the dilutions utilized.

Mutagenesis
To construct the GAP-43 CCAA double mutant, the template, wild type GAP-43, and the
primers, containing the appropriate codon mutations, were ordered from Integrated DNA
Technologies and two rounds of PCR performed. The first round consisted of two reactions that
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amplified GAP-43 from the area of mutation to the 5’ end of the cDNA and the area of mutation
to the 3’ end of the cDNA. The second round of PCR was performed using only the flanking
primers which contained the BamHI and HindIII restriction enzyme sites. The products of the
two rounds of PCR as well as the pAG3 expression plasmid were subsequently digested with
BamHI and HindIII restriction enzymes in separate reactions containing the 50μL reaction
volume and 1μL of each enzyme for 1 hour at 37oC. The reaction products were then run on
0.8% agarose gels at 90V until a separation of bands was evident. The appropriate bands were
determined by their migration pattern, excised, and then purified using a QIAGEN gel
purification kit. Once purified, the products were ligated into the expression plasmid, pAG3,
using T4 DNA ligase with a 3:1 ratio of insert to plasmid and subsequently used to transform
DH5α cells as outlined above. Clones containing the insert were submitted to sequencing at the
University of Chicago core sequencing facility. Mutations were confirmed before use in
experiments.

Cell fractionation
HEK293 cells stably expressing GAP-43 or GAP-43 CCAA were scraped into isotonic
lysis buffer (10mM tris pH7.4, 1mM EDTA, 0.5mM PMSF), incubated on ice for 10 minutes,
homogenized via 20 strokes through a ball bearing homogenizer with a 12μm clearance, and then
centrifuged at 5,000 x g for 5 minutes to remove nuclei. The supernatant from this spin was
centrifuged at 20,000 x g for 30 minutes at 4oC. The supernatant was labeled as the cytosolic
fraction and the pellet labeled as the membrane fraction.
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Co-immunoprecipitation
HEK293 cells were co-transfected with APPSWE and either FLAG-tagged GFP, FLAGtagged GAP-43, or FLAG-tagged GAP-43 CCAA using the protocol previously described. After
40 hours of co-expression, cells were lysed in a co-immunoprecipitation buffer consisting of
150mM NaCl, HEPES pH 7.0 and 0.5% Igepal. To precipitate protein complexes, 100ng of
rabbit anti-FLAG antibody was incubated with 5µl of lysate for 3 hours at 4oC with rocking after
which complexes were captured using paramagnetic beads conjugated to anti-rabbit antibodies.
After washing with co-immunoprecipitation buffer, complexes were released with citric acid, pH
3.0, and rebuffered by the addition of tris-HCl to pH 6.8. The captured protein complexes were
submitted to SDS-PAGE and Western blot analysis.

Densitometric analysis
Quantitation by optical density analysis of Western blot CCD images was performed on
three separate experiments using ImageJ software. Average optical density values were
compared using the unpaired t-test with GraphPad Prism.
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Results
GAP-43 silencing in N2a cells resulted in inconsistent results
Since APP and GAP-43 are known to reside in many of the same subcellular locations
(Figure 5) and to possess many similar physiological functions (Table 1), it is reasonable to
hypothesize that the two proteins may have a functional interaction. We predicted that if our
hypothesis is true, then the knockdown of GAP-43 in N2a cells would result in an alteration in
the level of APP metabolites as compared to untreated and scrambled control-treated groups. To
test our hypothesis, N2a cells were transiently transfected with one of four siRNA constructs,
either alone or in combination, each targeted against a different sequence within Gap-43 mRNA,
or a scrambled control (Table 3). Cells were harvested as described in Methods and the lysates
run on SDS-PAGE and probed with an anti-GAP-43 antibody to determine knockdown
efficiency. As evidenced in Figure 6, the combination of siRNA1-4, in equal parts, resulted in
the most efficient knockdown of GAP-43 expression in N2a cells. Therefore, we utilized this
combination in future experiments to determine the impact of GAP-43 knockdown on APP
processing.
Although the combination of GAP-43 siRNA1-4 appeared to knockdown GAP-43
expression efficiently in N2a cells, we were not able to collect consistent data between trials. At
the time, we were unaware of inconsistent transfection efficiencies in this particular cell line.
Importantly, the lack of conclusive data from this particular set of experiments did not rule out
the possibility of a functional relationship between APP and GAP-43; therefore, we next sought
to determine if overexpression of GAP-43 influences APP processing. For these experiments,
we chose the HEK293 human cell line originally derived from human embryonic kidney tissue.
Although these cells do not express detectable levels of GAP-43, they are easily transfectable
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and express all the components necessary for APP catabolism. Additionally, HEK293 cells are a
highly used line for the investigation of APP processing and thus, are a suitable line for the
exploration of an APP-GAP-43 interaction through expression protocols.

Figure 6: Efficiency of GAP-43 Silencing

Figure 6 depicts the efficiency of knockdown of each of the GAP-43 siRNA constructs, either singly or in
combination (equal parts), as well as that of a scrambled control (CTL) in N2a cells.

GAP-43 overexpression reduces APP C-terminal fragment levels in HEK293 cells
Due to the finding that GAP-43 co-immunoprecipitates with affinity-tagged APP in vivo
from mouse brain, as well as the fact that APP and GAP-43 have highly overlapping
physiological functions (Table 1) and are found within similar areas of the neuron (Figure 5),
we hypothesized that GAP-43 may influence the processing fate of APP (Norstrom et al., 2010).
Therefore, if GAP-43 influences APP processing, then we would expect to see changes in either
α-CTF fragments, β-CTF fragments, or both with overexpression of GAP-43 in HEK293 cells.
In order to test our hypothesis, we transiently transfected APPSWE with either GAP-43 or GFP
control into HEK293 cells as described in Methods. Cells were harvested approximately 40
hours after transfection and the lysates subjected to Western blot analysis. In order to determine
if GAP-43 overexpression impacts APP processing, the lysates were run on a gradient tricine
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polyacrylamide gel with a 10-16.5% acrylamide gradient and probed for C-terminal fragments of
APP, either α- or β-CTF, using the CTM1 antibody (Miller et al., 2016). Figure 7 depicts the
results of these experiments. As indicated in the figure, we observed a reduction in both α- and
β–CTF levels with co-expression of GAP-43 as compared to GFP as indicated by the weaker
signals migrating at approximately 10 and 12 kDa relative mass in the GAP-43 co-expressing
lane (Figure 7a – left panel). Importantly, no changes in full-length APP (migrating at
approximately 100 kDa relative mass on the Western blot) were observed in these experiments.
This observation indicates that GAP-43 expression does not depress the production of APP
metabolites by reducing APP expression. Expression of GAP-43 was confirmed by probing
portions of the membrane with an anti-GAP-43 antibody (Figure 7a - bottom panels).
Since wild type APP is known to be differentially processed by α- and β–secretases as
compared to APPSWE, we wanted to determine if GAP-43 overexpression on APP processing is
mutation specific (Mullan et al., 1992). Therefore, we also tested wild type APP under the same
paradigm to investigate potential differences in the processing fate of mutant and wild type APP
in the presence of GAP-43 overexpression. Since wild type APP does not bear the Swedish
mutation and thus, is not a very efficient substrate for β-secretase, we did not expect to observe a
reduction in β–CTF as we did with APPSWE; however, we did expect to see a reduction in α-CTF
since wild type APP is effectively cleaved by this secretase (Mullan et al., 1992; Lammich et al.,
1999). The results for this experiment are shown in the right panel of Figure 7a. Here again we
observed a reduction in C-terminal fragments without a concomitant reduction in full-length
APP; thus, we concluded that the effect of GAP-43 overexpression on APP processing is not
dependent on the presence of the Swedish mutation. Overexpression of GAP-43 was confirmed
by probing portions of the membrane with an anti-GAP-43 antibody.
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In order to determine if GAP-43 overexpression has a statistically significant impact on
the processing of APP by both α- and β-secretases, we quantified data from three independent
trials in which APPSWE was co-expressed with either GFP or GAP-43. To this end, densitometric
analysis was performed using ImageJ software and the values were compared using the unpaired
t-test with GraphPad Prism software. The results of this analysis indicated that GAP-43
overexpression has a statistically significant impact on the processing fate of APP by both α- and
β-secretases as the p value that resulted was less than 0.05. These results imply that GAP-43
may potentially interact with APP, either directly or indirectly, to reduce APP processing by both
α- and β-secretases. We next sought to explore whether membrane tethering was essential for
the influence of GAP-43 overexpression on APP processing.

Figure 7: GAP-43 Expression Reduces the Overall Processing of APP

A.

B.

Figure 7 A. Western blot of cell lysates from HEK293 cells co-expressing wild type APP (APPWT) or APPSWE and
GAP-43 reveal a reduction in the levels of C-terminal fragments in both cases relative to a control protein (GFP).
Both α- and β-CTF were reduced in the presence of GAP-43. B. Quantitation of C-terminal fragments by optical
density analysis of Western blot CCD images. Quantitation was performed using ImageJ software. Values were
compared using the unpaired t-test with GraphPad Prism. * indicates p < 0.05. N=3 for each analysis.
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Palmitoylation of Cys3 and Cys4 of GAP-43 is required for membrane association
Since APP is a type I transmembrane protein with a short cytoplasmic tail, and since
GAP-43 is targeted to the inner leaflet of the plasma membrane as a result of the palmitoylation
of cysteine residues 3 and 4, then it is logical to hypothesize that GAP-43 may interact with the
C-terminal intracellular domain of APP and by doing so, may potentially alter its processing fate
(Skene JH, 1989; Wasco et al., 1992; Wasco et al., 1993). If our hypothesis is true, then
mutating cysteine residues 3 and 4 to alanines, residues that cannot be palmitoylated, should
abolish the effect of GAP-43 overexpression on APP processing; consequently, no reduction in
α- or β-CTF levels should be observed with GAP-43 overexpression. To test our hypothesis,
point mutagenesis was carried out to mutate Cys3 and Cys4 to alanines to create the GAP-43
CCAA double mutant. Once the construct was created, we generated HEK293 cells stably
expressing either wild type GAP-43 or GAP-43 CCAA and separated the membrane fraction
from the cytosolic fraction through differential centrifugation as described in Methods. The two
fractions were run on SDS-PAGE and probed for GAP-43 using an anti-GAP-43 antibody to
determine distribution differences between wild type GAP-43 and the GAP-43 CCAA double
mutant. Since wild type GAP-43 transitions between cytosolic and membrane fractions, we
expected to observe wild type GAP-43 in both fractions, while we expected GAP-43 CCAA
double mutants only in the cytosolic fraction (Liu et al., 1994; Liang et al., 2002). As shown in
Figure 8, wild type GAP-43 was indeed found in both fractions, although the majority of the
signal was detected in the membrane fraction, suggesting that GAP-43 is primarily bound to the
membrane. Conversely, mutation of Cys3 and Cys4 to alanines completely abolished the
targeting of GAP-43 to the membrane fraction as shown in Figure 8. With this mutant, GAP-43
was only detectable in the cytosolic fraction. As a control for the relative purity of each fraction,

38

we performed the experiment using GFP, a soluble protein with no membrane-association
properties (Tsien, 1998). In this case, GFP was found to completely associate with the cytosolic
fraction (data not shown). This finding is significant because the change in the subcellular
distribution of GAP-43, from a predominantly membrane to a predominantly cytosolic
distribution, should consequently also abolish the impact of GAP-43 overexpression on the
processing fate of APP if that outcome is based on GAP-43 membrane targeting and a potential
APP-GAP-43 interaction. Thus, we next sought to determine if the impact of GAP-43
overexpression on APP processing requires the targeting of GAP-43 to the membrane fraction.

Figure 8: Palmitoylation of GAP-43 is Required for Membrane Association

Palmitate addition

Generation of
palmitoylation
deficient GAP43 mutants

MLCCMRRTKQ…
Palmitoylation
deficient mutant

Palmitoylation mutants
are found in cytosolic
fraction
M C

M C

MLAAMRRTKQ…
GAP-43 GAP-43
Wild-type CCAA

Figure 8 Left. Sequence of the first 10 amino acids of GAP-43. Palmitate is enzymatically added to cysteines 3 and
4. To determine the role of palmitoylation in the GAP-43 mediated alterations in APP metabolism, cysteines 3 and
4 were mutated to alanines, which do not contain a sulfur atom required for the thioester bond created during
palmitoylation. Right. HEK293 cells expressing GAP-43 or GAP-43 CCAA were fractionated into membrane (M)
and cytosolic (C) fractions and assayed for the relative presence of GAP-43 in each by Western blot. Wild type
GAP-43 was found in both fractions; conversely, GAP-43 CCAA was only found in the cytosolic fraction.
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Palmitoylation of Cys3 and Cys4 of GAP-43 is required for GAP-43 to exert its influence on APP
processing
Since palmitoylation of Cys3 and Cys4 is required for the association of GAP-43 with the
membrane fraction, and since APP is a type I transmembrane protein, we hypothesized that the
impact of GAP-43 overexpression on APP processing is most likely dependent upon
palmitoylation of these residues (Skene JH, 1989; Wasco et al., 1992; Wasco et al., 1993). If our
hypothesis is true, then co-expression of APPSWE and GAP-43 CCAA should not result in a
reduction in α- and β-CTF levels. To test this hypothesis, we transiently transfected HEK293
cells with APPSWE and either an empty vector control, GFP, wild type GAP-43, or GAP-43
CCAA. After approximately 40 hours of co-expression, the cells were harvested as described in
Methods. The lysates were then run on SDS-PAGE and probed for full length APP and α- and
β-CTF using the CTM1 antibody as well as for sAPPα using the 26D6 antibody to determine the
impact of GAP-43 CCAA overexpression on APP processing. The same lysates were also
probed for GAP-43 using an anti-GAP-43 antibody as well as for a loading control using an antiactin antibody. As indicated in Figure 9, when APPSWE was co-expressed with the empty vector
control or GFP, APPSWE was processed normally, with both α-CTF and β-CTF detectable in both
conditions (Figure 9 – lanes 2 and 3). Additionally, when APPSWE was co-expressed with wild
type GAP-43, we observed a reduction in α- and β-CTF levels as expected (Figure 9 – lane 4).
Conversely, when APPSWE was co-expressed with GAP-43 CCAA, the α- and β-CTF levels were
comparable to the control conditions and not reduced in level (Figure 9 – lane 5). This is strong
evidence that an APP-GAP-43 functional interaction is dependent on the membrane targeting of
GAP-43 via palmitoylation of Cys3 and Cys4. This finding is significant because it is the first
known report of a functional interaction between APP and GAP-43 with relevance to AD.
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Figure 9: Mutation of Cysteine Residues 3 and 4 to Alanines Inhibits the Effects of GAP-43
Overexpression on the Processing of APP

Figure 9: Mutation of cysteines 3 and 4 of GAP-43 to alanines results in a loss of the CTF-reducing effects of GAP43 overexpression. Co-expression of GAP-43 reduces APP C-terminal fragment levels (lane 4), but this effect is
lost when the palmitoylation consensus sequence is mutated (lane 5). Loading control probed with anti-actin
antibody indicates equal loading for each lane.
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Palmitoylation of Cys3 and Cys4 of GAP-43 is required for association with APP
Since we confirmed the necessity of Cys3 and Cys4 for the proper targeting of GAP-43 to
the membrane, as well as for the influence of GAP-43 overexpression on APP processing, we
next wanted to determine if the inability of the GAP-43 CCAA double mutant to influence the
processing of APP could be due to a lack of interaction between the two proteins. We
hypothesized that palmitoylation of Cys3 and Cys4 of GAP-43 is required for an APP-GAP-43
interaction since APP is a type I transmembrane protein and since GAP-43 must be
palmitoylated at Cys3 and Cys4 in order to associate to the membrane fraction (Skene JH, 1989;
Wasco et al., 1992; Wasco et al., 1993). Although previous results indicated that APP and GAP43 interact in vivo, we now predicted that the GAP-43 CCAA double mutant would not
immunoprecipitate along with APP in vitro, but that wild type GAP-43 would. To test our
prediction, HEK293 cells were transiently transfected with APPSWE and either FLAG-tagged
GFP, FLAG-tagged GAP-43, or FLAG-tagged GAP-43 CCAA. After 40 hours of coexpression, the cells were lysed and the protein complexes precipitated using a rabbit anti-FLAG
antibody as described in Methods. The captured protein complexes were submitted to SDSPAGE and Western blot analysis. To determine whether GFP, GAP-43, and GAP-43 CCAA
formed complexes with APP within the cells, membranes were probed with the CTM1 antibody.
As indicated in Figure 10, APP specifically immunoprecipitated with wild type GAP-43; it did
not immunoprecipitate with GFP as expected, nor did it immunoprecipitate with GAP-43 CCAA.
In three repeats of the experiment, we did not detect APP in the immunoprecipitate when it was
co-expressed with GAP-43 CCAA, indicating that Cys3 and Cys4 are required for an APP-GAP43 interaction. By extension, we concluded that membrane association, mediated at least in part
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by palmitoylation of GAP-43 at Cys3 and Cys4, is necessary for the functional interaction of
GAP-43 with APP.

Figure 10: APP does not Co-immunoprecipitate with GAP-43 CCAA

Figure 10: APPSWE was transiently co-expressed with FLAG-tagged versions of either GFP, wild type GAP-43, or
GAP-43 CCAA. Immunoprecipitation using an anti-FLAG antibody and Western blot detection of APP revealed
the presence of APP in wild type GAP-43 protein complexes, but not mutant GAP-43 or GFP complexes.
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Discussion
Importance of studying AD
AD is a devastating disorder that afflicts millions of individuals worldwide (alz.org,
2017). Its ever-increasing prevalence makes the study of this disease more and more relevant
(alz.org, 2017). Since no effective treatment options exist, it is important to shed light on the
molecular underpinnings of the onset and progression of this disorder. If we can determine why
and how Aβ accumulates in afflicted individuals, we can design tailored therapies aimed at
preventing just that. Although we do know that Aβ production results from a series of
proteolytic cleavages which involves multiple protein-protein interactions, we still do not fully
know or understand all of the pertinent protein interactions underlying the onset and progression
of AD. In order to design a truly efficacious therapy, more work needs to be done to fully
elucidate the complex pathophysiology of this disorder.

Importance of investigating a potential APP-GAP-43 interaction
In an attempt to address a possible factor in the onset and/or progression of AD, we
decided to investigate a potential novel protein-protein interaction between APP and GAP-43.
More specifically, we wanted to determine if GAP-43 interacts with APP in a way that alters its
metabolic processing. As previously discussed, the reasons we selected a potential APP-GAP-43
interaction for investigation were multiple. Briefly, Norstrom and colleagues found that GAP-43
immunoprecipitates with human APP695 fused to a C-terminal affinity tag in vivo from mouse
brain (Norstrom et al., 2010). Additionally, APP and GAP-43 have several overlapping
physiological functions (Table 1) and are known to localize to the same subcellular
compartments (Figure 5). Furthermore, GAP-43 expression is known to be altered in AD brain
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and has been found to colocalize in the brains of those with AD (Coleman et al., 1992; Masliah
et al., 1992; de la Monte et al., 1995; Cheetham et al., 1996; Masliah et al., 2001). For these
reasons, we hypothesized that GAP-43 may interact with APP in a bona fide protein complex
and that this interaction may influence the processing fate of APP. We wanted to determine the
effect of GAP-43 expression on the formation of APP metabolites as well as to confirm a
potential novel APP-GAP-43 interaction. The following paragraphs will summarize our findings
and their implications. Additionally, any discrepancies between our data and that found in
existing literature will be addressed.

Summary of findings, implications, and relation to established literature
In order to confirm and characterize a potential APP-GAP-43 interaction, we selected an
in vitro model system. The primary reason we opted to utilize an in vitro system was to
minimize variables so as to afford us greater experimental control and reduce interpretation
errors. For our in vitro system, we initially selected a mouse neuroblastoma cell line, N2a cells.
N2a cells were selected at the onset of our journey because their neuronal origin offered us the
ability to study the potential interaction in a more native setting. Although N2a cells were our
first choice for our in vitro system, we were not able to utilize them for the duration of our
studies due to transfection inefficiencies. This obstacle was discovered while investigating if
silencing GAP-43 expression in N2a cells influences APP processing (Figure 6). After
repeating the experiment several times, we noted our results were not consistent between trials.
While several variables could account for such an observation, we realized that it was our
inability to standardize the percentage of successfully transfected cells per experimental group
that hindered our ability to successfully interpret our data as our read out was relative change in
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the level of APP byproducts. Thus, we opted to utilize a cell line well known for its readily
transfectable nature, HEK293 cells (Thomas & Smart, 2005).
Although not of neuronal origin, HEK293 cells display several neuronal markers and
importantly, possess all of the cellular machinery necessary for complete APP metabolism;
consequently, HEK293 cells are used extensively within the AD research community (Shaw et
al., 2002; Norstrom et al., 2010; Gordon et al., 2013; Stepanenko & Dmitrenko, 2015).
Moreover, they are known for their readily transfectable nature and consistent behavior in culture
systems, serving as one of the most widely used cell culture model systems (Thomas & Smart,
2005). Once we switched our in vitro model system from N2a cells to HEK293 cells, our results
became consistent and we were thus able to begin interpreting our data. However, since
HEK293 cells do not express detectable levels of GAP-43, we could not repeat the siRNA
experiment in this cell line (Figures 7 and 9). Therefore, we chose to investigate the potential
impact of GAP-43 overexpression on APP metabolism.
When we overexpressed GAP-43 in HEK293 cells along with either wild type APP or
APPSWE, we observed a reduction in APP metabolites, both α-CTF and β-CTF, as compared to
the GFP control group (Figure 7). Since the reduction in APP byproducts was noted in both the
wild type APP- and APPSWE-transfected groups when co-transfected with GAP-43, we
concluded that this effect was independent of the Swedish mutation (Figure 7). To the best of
our knowledge, no paper has been published as of this writing in which a functional relationship
between GAP-43 and APP was investigated. However, correlative data between APP and GAP43 expression has been published. This collective body of data indicates that GAP-43 expression
is reduced in AD brain; more specifically, it indicates that GAP-43 expression is reduced in areas
of the AD brain associated with heavy plaque burden such as the hippocampus (Coleman et al.,
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1992; Masliah et al., 1992; de la Monte et al., 1995; Cheetham et al., 1996; Masliah et al., 2001).
Thus, by extrapolation, if GAP-43 expression is reduced in areas of AD brain associated with
increased Aβ deposition, then it is reasonable to argue that increasing GAP-43 expression in
these areas may have the opposite effect. This line of reasoning is further supported by the
findings of Routtenberg et al. in which GAP-43 overexpression was shown to result in enhanced
long-term potentiation and learning, processes negatively impacted in AD (Routtenberg et al.,
2000; Selkoe, 2011). Again, by extrapolation, since there is reduced GAP-43 expression in areas
of the brain impacted in AD, which is a disease characterized by impaired learning and memory,
then it is logical to assume that enhanced expression of GAP-43 in these areas may enhance
long-term potentiation and learning (Coleman et al., 1992; Masliah et al., 1992; de la Monte et
al., 1995; Cheetham et al., 1996; Masliah et al., 2001; Selkoe, 2011). Whether or not the impact
of GAP-43 overexpression on long-term potentiation and learning is due to its impact on APP
processing is unknown and should be explored further. However, our findings are in line with
the aforementioned literature.
Conversely, our findings are not in line with those published by Inoue et al. This group
found that silencing GAP-43 expression in HEK293 cells results in a decrease in Aβ production
(Inoue et al., 2015). A logical explanation for this difference could be that GAP-43 expression,
within a set expression range, results in a decrease in Aβ production. However, more studies
will need to be performed to better address this discrepancy. Although our data was not in line
with Inoue’s findings, it does not detract from the fact that we consistently observed a reduction
in α-CTF and β-CTF fragments when we overexpressed GAP-43 along with APP in hEK293
cells. Our finding is significant because it reveals a novel APP protein interaction that influences
the processing destiny of APP. Furthermore, this finding highlights the complexity of this
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disease and the importance of understanding each individual player in the onset and progression
of AD. We clearly have much more work that needs to be done in order to truly understand the
pathology of the disease. In order to try and further elucidate this new player in AD pathology,
we next sought to characterize the parameters required for GAP-43 to exert this effect.
Since APP is a type-I transmembrane protein and since GAP-43 is targeted to the
membrane as a result of palmitoylation of cysteine residues 3 and 4, we wanted to determine if
palmitoylation of these residues is necessary for GAP-43 to influence APP processing (Skene
JH, 1989; Wasco et al., 1992; Wasco et al., 1993). To this end, point mutagenesis was carried
out to mutate Cys3 and Cys4 to alanines, residues that cannot be palmitoylated. When Cys3 and
Cys4 of GAP-43 were mutated to alanines, we noted a change in the distribution of GAP-43
(Figure 8). Typically, GAP-43 fluctuates between the membrane and cytosolic fractions with
the majority localized to the membrane compartment (El-Husseini et al., 2001; Liang et al.,
2002). However, upon mutation of Cys3 and Cys4 to alanines, the membrane targeting of GAP43 was completely abolished as indicated by the complete absence of signal in the membrane
fraction (Figure 8). With the GAP-43 CCAA double mutant, we were only able to detect GAP43 in the cytosolic fraction (Figure 8). This is in agreement with other studies that have verified
the necessity of the palmitoylation of GAP-43 at Cys3 and Cys4 for the membrane targeting of
GAP-43 (El-Husseini et al., 2001; Liang et al., 2002). Abolishing the targeting of GAP-43 to the
membrane fraction was important for our studies as we wanted to determine if the impact of
GAP-43 overexpression on the metabolic processing of APP could potentially be due to a
physical interaction between the two proteins. Although it is conceivable that GAP-43 could
effect a change in APP processing via targeting to a soluble target, as later determined,
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membrane association was essential for the modulation of APP processing by GAP-43
overexpression.
When GAP-43 CCAA was co-expressed with APPSWE in HEK293 cells, the impact of
GAP-43 overexpression on APP processing was abolished (Figure 9). This result implied that
the palmitoylation of Cys3 and Cys4 of GAP-43 is necessary for a functional interaction between
APP and GAP-43. We further deduced that GAP-43 may influence the processing fate of APP
through a protein-protein interaction, either directly or indirectly via a multi-protein complex.
This is the first known report to show that GAP-43 is not only able to influence the processing of
APP, but that this effect is dependent upon the palmitoylation of Cys3 and Cys4 of GAP-43.
Since we noted that GAP-43 CCAA did not impact the processing fate of APP, we wanted to
determine if its inability to do so could be due to a lack of a physical interaction between the
GAP-43 CCAA double mutant and APP.
To test our hypothesis, we co-expressed FLAG-tagged versions of either wild type GAP43, GAP-43 CCAA, or GFP along with APPSWE in HEK293 cells and, using an anti-FLAG
antibody, immunoprecipitated complexes. We then probed for the presence of APP in the
complexes using an anti-APP antibody after running the immunoprecipitates via SDS-PAGE.
When APPSWE was co-expressed with FLAG-tagged versions of either GAP-43 CCAA or GFP,
we were not able to detect APP in the immunoprecipitate, thus indicating that the proteins do not
interact in vitro (Figure 10). However, when APPSWE was co-expressed with FLAG-tagged
GAP-43 in HEK293 cells, we did detect APP in the immunoprecipitate (Figure 10). These
findings agree with those published by Norstrom et al. as they found that GAP-43 coimmunoprecipitates with APP in vivo from mouse brain (Norstrom et al., 2010). Although no
other studies have demonstrated an interaction between APP and GAP-43, Inoue et al.
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demonstrated an interaction between GAP-43 and γ-secretase (Inoue et al., 2015). The findings
of Inoue et al. do not contradict ours as it may be that GAP-43 interacts with APP in a multiprotein complex, a complex which may include γ-secretase.

Significance
As a result of our studies, we were able to successfully confirm and characterize a novel
protein-protein interaction between APP and GAP-43. These studies reveal that through the
palmitoylation of Cys3 and Cys4, GAP-43 is targeted to the membrane and moreover, that the
targeting of GAP-43 to the membrane is essential for an interaction between APP and GAP-43.
Furthermore, we found that the interaction of GAP-43 with APP reduces the accumulation of
byproducts of APP metabolism. These findings represent the first report of a functional APPGAP-43 protein-protein interaction. Additionally, these findings indicate that GAP-43 may play
a relevant role in AD pathogenesis by modulating APP processing. Although this discovery is
very important, much work still needs to be done.

Future directions
Although we have shed light on a new factor that influences the processing of APP as it
relates to AD pathology, it is important to continue to test the mechanics and significance of this
interaction. It will be important to determine how GAP-43 expression influences the other
byproducts of APP metabolism. By determining the impact of GAP-43 expression on the other
metabolites of APP, we will gain a better understanding of how GAP-43 influences APP
processing. Additionally, it will be important to determine at which subcellular sites the two
proteins interact. Do they interact at more than one site? Is the physiological outcome the same
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at different sites? Based on the reduction of both α- and β–CTF levels, the subcellular location
of a potential APP-GAP-43 interaction is likely to be early in the secretory pathway. That is,
since both α- and β–CTF levels are reduced, the interaction seems to be guiding APP towards
sites capable of both α- and β-secretase activity, and possibly γ-secreatse activity, which is
primarily the early secretory pathway, and away from sites predominantly responsible for either
α- or β–secretase activity, which is the plasma membrane and late endosomal pathway
respectively (Chow et al., 2010). However, this hypothesis needs experimental validation.
Further tests will need to be conducted in order to determine if GAP-43 interacts directly with
APP and/or α- or β–secretase or, as the findings of Inoue indicate, γ-secreatse (Inoue et al.,
2015). Additionally, it will be important to determine if this effect is cell line specific. If the
impact of GAP-43 overexpression on APP processing is not limited to HEK293 cells, testing
should be conducted in an in vivo system. It will be interesting to see if this interaction does
indeed have any relevance to the onset and progression of AD.
While we do not currently have the answers to these questions, it is an exciting possibility
that should be explored further as this finding illuminates a means by which APP processing is
influenced. Once we can paint a clear picture of all the factors that influence APP processing
and Aβ formation and deposition, we can then design a therapy to combat the disease.

Conclusions
As a result of the experiments conducted throughout the course of this study, we determined:
1) GAP-43 overexpression reduces APP processing. 2) Palmitoylation of Cys3 and Cys4 of
GAP-43 is required for membrane targeting of GAP-43. 3) Membrane targeting of GAP-43 is
required for GAP-43 to impact APP processing and to form a complex with APP in vitro. Due to
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the sum total of these findings, we concluded that GAP-43 interacts with APP in a manner that
alters the prcoessing fate of APP and that this functional interaction is dependent upon the
palmitoylation of Cys3 and Cys4 of GAP-43 (Figure 11).

Figure 11: Study Conclusions

Figure 11: The above figure graphically depicts the conclusions from our studies: 1) GAP-43 functionally interacts
with APP in a way that alters its processing fate. 2) The APP-GAP-43 interaction is dependent on the palmitoylation
of Cys3 and Cys4 of GAP-43.
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